4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

March 28, 2024

https://www.globenewswire.com/news-release/2024/03/28/2853925/0/en/4DMT-Announces-Update-on-Regulatory-Interactions-and-Development-Path-for-4D-710-for-Treatment-of-Cystic-Fibrosis.html

EMERYVILLE, Calif., March 28, 2024 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq:FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced an update on its regulatory interactions and development path for 4D-710, an aerosolized genetic medicine for the treatment of CF lung disease.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.